Shares of Axovant Sciences Ltd. (NASDAQ:AXON) swings enthusiastically in regular trading session, it increase of 23.65% to close at $1.49. Axovant Sciences (AXON) revealed that Gavin Corcoran, MB BCh, FACP, will join the Company as Executive Vice President of Research & Development, and Michael Hayden, MB ChB, PhD, FRSC, has been appointed as a senior scientific advisor to the company and Chairman of Axovant’s newly established Scientific Advisory Board.
“I am pleased to welcome Gavin and Michael to the Axovant team,” said PavanCheruvu, MD, Chief Executive Officer of Axovant. “Since starting as CEO in February, I have been focused on transforming Axovant into a leaner organization, introducing heightened standards of quality and excellence throughout the business, and establishing a new pipeline strategy. We are now poised for growth, and I am excited to have Gavin and Michael join us as we look toward expanding our pipeline in the coming months.”
“I am very excited to join Axovant at this turning point,” said Dr. Corcoran. “I look forward to working closely with Pavan and the senior management team to bring new investigational medicines into the portfolio as we build upon Axovant’s capabilities in research and development. We have a wonderful opportunity to develop life-changing medicines for patients with CNS diseases. I am also eager to leverage the Roivant platform to accelerate the development of Axovant’s pipeline.”
“I share Pavan’s vision of rebuilding the company on a foundation of transformative science and I look forward to expanding Axovant’s Scientific Advisory Board,” said Dr. Hayden. “I have been very impressed with the caliber of the Axovant team and am excited about the future growth of the company.” The stock is going forward its fifty-two week low with 46.08% and lagging behind from its 52-week high price with -94.67%. AXON last month stock price volatility remained 11.14%.
TransEnterix, Inc. (NYSE:TRXC) shares scoring 8.95% to $3.41 in active trade session, while looking at the shares volume, around 18.02 Million shares have changed hands in this session.
TransEnterix Inc. shares (TRXC) reported that it has won U.S. Food and Drug Administration approval for expanded indications for its Senhance Surgical System. Specifically, the company said the FDA has cleared the medical device company for laparoscopic inguinal hernia and laparoscopic cholecystectomy (gallbladder removal) surgery.
“There are approximately 760,000 inguinal hernia and 1.2 million laparoscopic cholecystectomy procedures performed annually in the U.S.,” the company said. “With this clearance, Senhance System’s total addressable annual procedures in the U.S. have more than doubled to over three million.” Senhance is now approved for laparoscopic colorectal, gynecologic, inguinal hernia and cholecystectomy surgery. The firm has institutional ownership of 28.90%, while insider ownership included 2.10%. TRXC attains analyst recommendation of 1.60 with week’s performance of -0.58%. Investors looking further ahead will note that the Price to next year’s EPS is 12.50%.